Lenoir Marion, Wienke Jörg, Fardao-Beyler Frédérique, Roese Nadine
Biocodex SAS, 7 Avenue Gallieni, F-94257, Gentilly, France.
, Ritastrasse 2, D-40589 Düsseldorf, Germany.
Probiotics Antimicrob Proteins. 2025 Feb;17(1):315-327. doi: 10.1007/s12602-023-10151-w. Epub 2023 Sep 13.
Irritable bowel syndrome (IBS) is one of the disorders most frequently diagnosed by gastroenterologists. Probiotics are promising tools for the management of IBS. The objective of the present study was to evaluate the effectiveness and tolerability of a probiotic (Bifidobacterium longum 35624) in adults (aged 18 or over) with IBS (as defined by the Rome IV criteria). In an open-label, observational, post-market study conducted in Germany, adults with IBS and a prior recommendation for the intake of B. longum 35624 were recruited by family physicians. During the 8-week course of treatment, the study participants filled out a weekly questionnaire that enabled calculation of a total IBS symptom score (TISS, the sum of abdominal pain, bloating, passage of gas, constipation, and diarrhea individual symptom scores) and the well-known IBS severity scoring system (IBS-SSS) score. Thirty-seven patients were included. The course of B. longum 35624 was associated with a significant reduction (43.4%) in the TISS vs. baseline. The mean individual symptom grades for passage of gas and bloating fell significantly from "moderate" at baseline to "very mild to mild" after 8 weeks of treatment, whereas those for abdominal pain and diarrhea fell significantly from "mild to moderate" to "very mild to mild." Over 60% of the participants achieved clinically meaningful reductions in the TISS (> 30%) and the IBS-SSS score (> 50 points). The effectiveness of B. longum 35624 was rated as "good to satisfactory" by study participants and the investigating physicians. One mild adverse event (nausea) was potentially linked to the study treatment. We conclude that an 8-week course of B. longum 35624 was associated with significant, clinically meaningful symptom relief in a typical population of adult patients with IBS.
肠易激综合征（IBS）是胃肠病学家最常诊断出的疾病之一。益生菌是管理IBS的有前景的工具。本研究的目的是评估一种益生菌（长双歧杆菌35624）对符合罗马IV标准定义的18岁及以上IBS成年患者的有效性和耐受性。在德国进行的一项开放标签、观察性上市后研究中，家庭医生招募了患有IBS且之前被推荐摄入长双歧杆菌35624的成年患者。在为期8周的治疗过程中，研究参与者每周填写一份问卷，用于计算IBS症状总分（TISS，即腹痛、腹胀、排气、便秘和腹泻各自症状评分的总和）以及著名的IBS严重程度评分系统（IBS-SSS）得分。纳入了37名患者。与基线相比，长双歧杆菌35624疗程使TISS显著降低（43.4%）。排气和腹胀的平均个体症状等级从基线时的“中度”显著降至治疗8周后的“非常轻度至轻度”，而腹痛和腹泻的症状等级则从“轻度至中度”显著降至“非常轻度至轻度”。超过60%的参与者在TISS（>30%）和IBS-SSS评分（>50分）方面实现了具有临床意义的降低。研究参与者和调查医生将长双歧杆菌35624的有效性评为“良好至满意”。有1例轻度不良事件（恶心）可能与研究治疗有关。我们得出结论，在典型的成年IBS患者群体中，8周长双歧杆菌35624疗程可带来显著的、具有临床意义的症状缓解。
